Trial Profile
A Randomized, Double Blind, Placebo Controlled, Phase 2 Study to Assess the Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of LNP1892 (Monotherapy) in Chronic Kidney Disease (CKD) Patients with Secondary Hyperparathyroidism (SHPT), On Dialysis and Not on Dialysis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Jul 2019
Price :
$35
*
At a glance
- Drugs LNP 1892 (Primary)
- Indications Secondary hyperparathyroidism
- Focus Therapeutic Use
- Sponsors Lupin
- 17 Jun 2019 Status changed from recruiting to completed.
- 13 Dec 2017 New trial record